Roble Belko & Company’s Bioverativ Inc. Common Stock BIVV Stock Holding History

Roble Belko & Company’s Portfolio BIVV Stock Details BIVV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-694	Closed	-$37K	–	350
2017 Q4	$37K	Hold	694	–	–	0.02%	133
2017 Q3	$40K	Hold	694	–	–	0.02%	101
2017 Q2	$42K	Hold	694	–	–	0.02%	96
2017 Q1	$38K	Buy	+694	New	+$34.2K	0.02%	99

Other funds holding BIVV

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

ACS

Archford Capital Strategies Swansea, Illinois $987M AUM 29.31% 1-Year Est. Return

Roble Belko & Company's BIVV Position: Q1 2018 in Review

Roble Belko & Company sold out of Bioverativ Inc. Common Stock (BIVV) in Q1 2018, closing a stake of 694 shares — an estimated $37K sold.

Roble Belko & Company first reported a position in BIVV in Q1 2017 and held it in 4 quarters. The position peaked at $42K in Q2 2017. 2 funds tracked by Wall St. Rank hold BIVV as of Q1 2018.

Roble Belko & Company reported no remaining Bioverativ Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
Roble Belko & Company sold 694 Bioverativ Inc. Common Stock shares in Q1 2018, an estimated $37K.
Roble Belko & Company first reported a position in Bioverativ Inc. Common Stock in Q1 2017 and held it in 4 quarters.
Roble Belko & Company's Bioverativ Inc. Common Stock position peaked at $42K in Q2 2017.
2 funds tracked by Wall St. Rank held Bioverativ Inc. Common Stock as of Q1 2018.

Based on Roble Belko & Company's 13F filing for Q1 2018, filed 14 May 2018.